SOHO ANNUAL MEETING 2024

Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database

Nishanth Thalambedu MD, Zhongning Chen MD, Sruthi Vellanki MD, MBA, FACP, Anup Kumar Trikannad Ashwini Kumar MD, MS, FACP , Ankur Varma MD, MPH,
University of Arkansas for Medical Sciences (UAMS), Little Rock, USA

UAMS University of Arkansas for Medical Sciences

INTRODUCTION


- NLPHL is a rare subtype of Hodgkin lymphoma, recently renamed to nodular lymphocyte-predominant B-cell lymphoma.
- Accounts for <5% of all Hodgkin lymphoma cases in the U.S.
- Limited research on demographics and survival outcomes due to its rarity

METHOD

- Retrospective analysis using SEER data (2000-2020).
- 1525 NLPHL cases identified.
- Data categorized by Ann Arbor staging (early vs. advanced).
- Subgroup analyses on stage-survival correlation.

RESULTS

- Early Stage (n=1097): 50.1% <40 years, 70.1% male, 60.2% Caucasian.
- Advanced Stage (n=428): 46.9% <40 years, 70.3% male, 61.2% Caucasian.
- 10-Year Median Overall Survival: Early Stage: 88.3%, Advanced Stage: 77.3%.
- HR for survival difference between stages: 2.03 (P<0.001).



	Early Stage	Advance Stage
Age <40	50.1% (549/1097)	46.9% (201/428)
Age >40	49.9% (548/1097)	53.1% (227/428)
Male	70.1% (769/1097)	70.3% (301/428)
Female	29.9% (328/1097)	29.7% (127/428)
Caucasians	60.2% (660/1097)	61.2% (262/428)
African Americans	21.6% (237/1097)	23.1% (99/428)
Hispanics	12.3% (135/1097)	10.9% (47/428)
American Indian/Alaska Native	0.4% (5/1097)	0.4% (2/428)
Asian/Pacific Islander	5.5%(60/1097)	4.2% (18/428)
Stage	I : 644 II: 453	III: 305 IV: 123
10 year Median OS	88.3%	77.3%

Table 1: Demographics and Survival of Nodular lymphocyte predominant hodgkin lymphoma(NLPHL) patients diagnosed between 2000-2020

CONCLUSIONS

- NLPHL predominantly affects males and Caucasians.
- Early-stage patients have significantly better survival outcomes.
- Emphasizes the need for aggressive treatment strategies for advanced-stage NLPHL patients.

CONTACT INFORMATION

Email ID: atrikannad@uams.edu